GL1X · GenesisL1 explorer

MolNFT v1 · #61156 · protein

Structure of DOCH66Y in complex with the C-terminal domain of phd

3DD7 · Death on curing protein: “Structure of DOCH66Y in complex with the C-terminal domain of phd”. X-ray diffraction, 1 ligand (BR), 2 pockets (best druggability 0.57). MolNFT v1 #61156 on GenesisL1: 3D structure, binding sites and…

PDB
3DD7
Type
protein
Length
285 residues
Chains
4
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Death on curing protein; Prevent host death protein
UniProt
Q06259, Q06253
Ligands
BR
Pockets
2 · best druggability 0.57

Structure

x-ray diffraction · 4 distinct chains · 68% helix, 1% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ADeath on curing proteinprotein12366% helix, 2% strandQ06259
BPrevent host death proteinprotein1883% helix, 0% strandQ06253
CDeath on curing proteinprotein12266% helix, 0% strandQ06259
DPrevent host death proteinprotein2277% helix, 0% strandQ06253

Ligands and binding sites

  • BR · Bromide ion · ion · 16 copies · chains A, B, C, D

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12570.570.7833BR
21330.390.7424BR

Interfaces

4 interfaces between chains.

  • C–D · 1035 Ų buried · 20 hydrogen bonds · protein-protein
  • A–B · 900 Ų buried · 16 hydrogen bonds · protein-protein
  • A–C · 286 Ų buried · 3 hydrogen bonds · protein-protein
  • B–C · 64 Ų buried · 0 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 modified (engineered).

Compared structures

  • 3DD7 · Structure of DocH66Y in complex with the C-terminal domain of Phd · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.